You are here: Industry Insights > Janssen

News List

XBiotech to sell anti- IL-1⍺ antibody bermekimab to Janssen in $1.3bn deal pharmaceutical-business-review
December 11, 2019
XBiotech has agreed to offload its human antibody bermekimab to Janssen Biotech, a subsidiary of Janssen Pharmaceutical Company of Johnson & Johnson, in a deal worth up to $1.35bn.
Janssen Announces Initial Results for BCMA CAR-T Therapy JNJ-4528 americanpharmaceuticalreview
December 11, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced initial results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528) ...
Janssen to acquire bermekimab’s rights from XBiotech for $750m pharmaceutical-technology
December 10, 2019
Janssen Biotech has signed a definitive agreement to buy rights to XBiotech’s investigational monoclonal antibody, bermekimab, for a cash consideration of $750m.
Janssen Submits TREMFYA Application to FDA for Psoriatic Arthritis americanpharmaceuticalreview
September 18, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking ...
EC expands label of Janssen’s Stelara to include ulcerative colitis pharmaceutical-technology
September 10, 2019
Johnson & Johnson subsidiary Janssen has announced the European Commission (EC) has approved Stelara (ustekinumab) for patients with moderately to severely active ulcerative colitis (UC).
Eli Lilly’s Taltz outperforms Janssen’s Tremfya in psoriasis pharmaceutical-technology
August 15, 2019
Eli Lilly has announced that its drug Taltz (ixekizumab) outperformed rival Janssen’s Tremfya in the Phase VI IXORA-R trial studying patients with moderate-to-severe plaque psoriasis.
Alligator Bioscience regains cancer asset rights from Janssen pharmaceutical-technology
August 01, 2019
Swedish biotech firm Alligator Bioscience has regained the global rights for tumour-directed immunotherapy ADC-1013 (JNJ-64457107) from Janssen Biotech.
Janssen Reports Positive Top-Line Phase 3 Results for Ponesimod americanpharmaceuticalreview
July 29, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive top-line results from the Phase 3 OPTIMUM study, which evaluated the efficacy and safety of ponesimod compared to Aubagio® (teriflunomide) in adults with ...
Janssen files submission for subcutaneous Darzalex in Europe pharmaceutical-technology
July 23, 2019
Janssen Pharmaceutical has submitted an application to the European Medicines Agency (EMA) seeking approval for subcutaneous formulation of Darzalex (daratumumab) to treat multiple myeloma.
Janssen Reports Top-Line Phase 3 Results for TREMFYA® americanpharmaceuticalreview
June 20, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced top-line results from the Phase 3 DISCOVER 1 and 2 studies, which evaluated the efficacy and safety of guselkumab compared to placebo in adult patients with active moderate to severe psor

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page